Perspective
Published on 02 Feb 2024
External comparators and estimands
Frontiers in Drug Safety and Regulation
doi 10.3389/fdsfr.2023.1332040
- 1,348 views
- 3 citations
Volumes
26 Publications
Review
Published on 26 Jan 2024
Conducting and interpreting disproportionality analyses derived from spontaneous reporting systems
Frontiers in Drug Safety and Regulation
doi 10.3389/fdsfr.2023.1323057
- 6,042 views
- 21 citations
Perspective
Published on 24 Jan 2024
External Comparator Cohort studies - clarification of terminology
Frontiers in Drug Safety and Regulation
doi 10.3389/fdsfr.2023.1321894
- 2,008 views
- 1 citation
Review
Published on 21 Dec 2023
A review of the prescribing culture of anti-depressants across government districts in Northern Ireland
Frontiers in Drug Safety and Regulation
doi 10.3389/fdsfr.2023.1303572
- 1,335 views
- 1 citation
Review
Published on 14 Dec 2023
Safety of corticosteroid therapy in sarcoidosis treatment
Frontiers in Drug Safety and Regulation
doi 10.3389/fdsfr.2023.1319931
- 889 views
Correction
Published on 04 Dec 2023
Corrigendum: An industry perspective on the use of machine learning in drug and vaccine safety
Frontiers in Drug Safety and Regulation
doi 10.3389/fdsfr.2023.1244115
- 489 views
Original Research
Published on 23 Nov 2023
Drug target, class level, and PathFX pathway information share utility for machine learning prediction of common drug-induced side effects
Frontiers in Drug Safety and Regulation
doi 10.3389/fdsfr.2023.1287535
- 1,030 views
Review
Published on 07 Nov 2023
Promising treatment biomarkers in asthma
Frontiers in Drug Safety and Regulation
doi 10.3389/fdsfr.2023.1291471
- 1,466 views
- 1 citation
Original Research
Published on 15 Sep 2023
Identification of small cell lung cancer patients who are at risk of developing common serious adverse event groups with machine learning
Frontiers in Drug Safety and Regulation
doi 10.3389/fdsfr.2023.1267623
- 652 views
Methods
Published on 06 Sep 2023
Navigating a transforming landscape: the evolving role of pharmacovigilance physicians in drug development and implications for future challenges and training requirements
Frontiers in Drug Safety and Regulation
doi 10.3389/fdsfr.2023.1257732
- 2,943 views
- 2 citations
Original Research
Published on 25 Aug 2023
The risk of preterm labor after COVID-19 vaccination before and during pregnancy
Frontiers in Drug Safety and Regulation
doi 10.3389/fdsfr.2023.1235051
- 1,833 views
- 2 citations
Original Research
Published on 04 Aug 2023
Evaluation of cardiovascular toxicity of the atezolizumab and bevacizumab combination
Frontiers in Drug Safety and Regulation
doi 10.3389/fdsfr.2023.1213771
- 1,541 views
Review
Published on 04 Aug 2023
Mucoadhesive polymers in substance-based medical devices: functional ingredients or what else?
Frontiers in Drug Safety and Regulation
doi 10.3389/fdsfr.2023.1227763
- 3,632 views
- 4 citations
Original Research
Published on 17 Jul 2023
Signal management and risk minimization strategy: a case study on obinutuzumab and non-overt disseminated intravascular coagulation
Frontiers in Drug Safety and Regulation
doi 10.3389/fdsfr.2023.1194683
- 978 views
- 1 citation
Methods
Published on 29 Jun 2023
Elements to assess the quality of information of case reports in pregnancy pharmacovigilance data—a ConcePTION project
Frontiers in Drug Safety and Regulation
doi 10.3389/fdsfr.2023.1187888
- 1,777 views
- 3 citations
Editorial
Published on 31 May 2023
Editorial: Substance-based medical devices for human health: a challenge of efficacy, safety, and sustainability
Frontiers in Drug Safety and Regulation
doi 10.3389/fdsfr.2023.1222790
- 697 views